LYMPHOMAS

Time-to-next treatment and overall survival were improved in a real-world study evaluating patients who received rituximab maintenance after first-line treatment with bendamustine and rituximab or R-CHOP in patients with mantle cell lymphoma, according to a retrospective analysis presented at the European Hematology Association 2021 Virtual conference.

Axicabtagene ciloleucel improved outcomes for patients with relapsed/refractory follicular lymphoma over currently available therapies, according to data from a comparative analysis of the ZUMA-5 and SCHOLAR-5 trials.

Naratuximab emtansine in combination with rituximab showed deep responses and a duration of response that was not reached in patients with relapsed or refractory diffuse large B-cell lymphoma, according to findings from a phase 2 trial presented during the EHA 2021 Virtual Congress.

A favorable safety profile and promising efficacy was seen with C-CAR066, a novel 2nd generation chimeric antigen receptor T-cell therapy targeting the CD20 antigen, in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma who failed with prior CD19 CAR T-cell therapy.

A second-generation 4chimeric antigen receptor (CAR) T-cell agent has induced responses in patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated in a phase 1 study.

Increased efficacy was observed with the combination of mosunetuzumab with polatuzumab vedotin in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

AB-205 demonstrated robust effects and an encouraging safety profile in patients with systemic lymphoma undergoing high-dose therapy and autologous hematopoietic stem cell transplantation.

The FDA has accepted a supplemental new drug application for zanubrutinib for the treatment of adult patients with marginal zone lymphoma who have received 1 prior anti-CD20-based therapy. The agent was also granted priority review, with a Prescription Drug User Fee Act target action date of September 19, 2021.

Regeneron is resuming enrollment of patients with follicular lymphoma and diffuse large B-cell lymphoma in monotherapy trial of odronextamab after the FDA lifted the partial clinical hold placed on the agent in December 2020.

The LOTIS-2 phase 2 study of loncastuximab tesirine continued to show durable responses and tolerability in relapsed or refractory patients with DLBCL, according to the most recent published results.

Zanetta Lamar, MD, discussed the efficacy of tafasitamab in combination with lenalidomide in the clinical trial setting.

Patients with relapsed or refractory aggressive large B-cell lymphoma showed promising results from the administration of lisocabtagene maraleucel in both inpatient and outpatient non–university hospital settings.

Constantine S. Tam, MD, discusses how ibrutinib plus venetoclax regimen from the SYMPATICO 2938 trial may fit in the relapsed/refractory mantle cell lymphoma setting.

In an interview with Targeted Oncology, Bishop, discussed how CAR T cells have reshaped the treatment landscape, the future of their use, and their potential in solid tumors.

The National Comprehensive Cancer Network has added loncastuximab tesirine-lpyl to the NCCN Clinical Practice Guidelines in oncology for B-cell lymphomas.

The relapse-free survival benefit observed with rituximab maintenance added to autologous stem cell transplant suggests that the treatment strategy may help with disease eradication.

Here is a look back at the FDA happenings from the month of April 2021.

In an interview with Targeted Oncology, Scott R. Solomon, MD, a medical oncologist with the Blood and Marrow Transplant Program, Leukemia and Cellular Immunotherapy Program at the Northside Hospital Cancer Institute, discussed the efficacy of liso-cel in large B-cell lymphoma patients with prior anti-CD19 exposure and future research.

The FDA has granted approval top loncastuximab tesirine for the treatment of relapsed or refractory diffuse large B-cell lymphoma, according to a press release from ADC Therapeutics.

When given at the recommended phase 2 dose, lenzilumab in combination with taxicabtagene ciloleucel, induced a 100% objective response rate while showing no severe cytokine release syndrome cases or severe neurotoxicity in patients with relapsed or refractory diffuse large B-cell lymphoma.

Citing clinical pearls from her own experience in working with patients with relapsed/refractory follicular lymphoma, Kami Maddocks, MD, gives advice to colleagues in their efforts to combat follicular lymphoma.

Kami Maddocks, MD, lists the future directions and unmet needs present in treating relapsed/refractory follicular lymphoma.

The challenges faced in treating patients beyond second-line treatment are addressed. Kami Maddocks, MD, reviews the frequency of patients who require third- and fourth-line treatment, in addition to the factors that affect treatment decisions in later lines of therapy.

Considerations for subsequent treatment options in the second-line setting for patients with follicular lymphoma are reviewed by an expert hematologist.

Kami Maddocks, MD, highlights what findings may trigger a change in therapy or the introduction of a new agent into a patient’s current treatment.